Investor Information Materials
Artelo Biosciences, Inc.
(Nasdaq: ARTL)
52 Week Range: $0.45-$3.67
Approx. MktCap: $20 Million
Wall Street coverage by Ladenburg Thalmann and Maxim Group.

Artelo In The News

Benzinga Cites Potential of CBD-based drugs going mainstream

Artelo At A Glance

Recent Publications

The Pharmacological Effects of 
Plant-Derived versus Synthetic
 Cannabidiol in Human Cell Lines

The Effects of CBD and TMP 
Co-Administration in Cancer

Artelo Biosciences
Corporate Presentation

Slide Presentation

Visit Artelo Biosciences's website

Important notice, please read: The information and statistical data contained herein may contain forward-looking statements that reflect the company’s intentions, expectations, assumptions, or beliefs concerning future events, including, but not limited to, expectations with respect to FDA and other regulatory bodies approval of new products, technology, and product development milestones, the ability of the company to leverage its product development and negotiate favorable collaborative agreements, the commencement of sales, the size of market opportunities with respect to the company’s product candidates and sufficiency of the company’s cash flow for future liquidity and capital resource needs and other risks identified in the Risk Factor Section of the company’s Annual Report on Form 10-K and any subsequent reports filed with the SEC. We do not undertake to advise you as to any change in this information. The forward-looking statements are qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. In addition, significant fluctuations in quarterly results may occur as a result of varying milestone payments and the timing of costs and expenses related to the company’s research and development programs. This is not a solicitation of any offer to buy or sell. Redington, Inc. is paid by subject company as an investor relations advisor, and its employees or members of their families may from time to time own an equity interest in companies mentioned herein.

Call 212 926-1733